A Century After the Eugenics Movement, the U.S. Is Again Barring Disabled Immigrants
By Emma Cieslik,
Ms. Magazine
| 11. 20. 2025
A revived “public charge” standard directs officers to deny visas to people with disabilities, chronic illnesses and age-related conditions—echoing the exclusionary policies of the early 20th century.
Photo by The New York Public Library on Unsplash
This piece includes sanist slurs used in the late 19th and early 20th centuries.
This month, Secretary of State Marco Rubio instructed visa officers to consider obesity and other chronic health conditions, such as heart disease, cancer and diabetes, as justification to deny people visas to the United States. The guidance—along with direction that visa officers can reject visa applications for people beyond retirement age and if their dependents are elderly or disabled—is part of a “public charge” rulethat allows the government to deny visas and green cards if the person might use social welfare programs or be institutionalized.
Many were outraged and shocked, observing the Trump administration’s new expansion of the “public charge” rule—directing visa officers to deny entry to people with disabilities, chronic illnesses or age-related conditions—as a modern revival of eugenic immigration policy designed to exclude, control and institutionalize disabled and marginalized people. The “public charge” rule is not new, but this new definition seeks to restrict citizenship on the basis of possible institutionalization as the Trump...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...